Neonatal Glycogen Storage Disease Ia
Jinping Zhang,Wenjing Shi,Chao Chen
DOI: https://doi.org/10.1016/j.pedneo.2014.05.003
IF: 2.586
2015-01-01
Pediatrics & Neonatology
Abstract:Glycogen storage disease Ia (GSD Ia) is an autosomal recessive inborn error of carbohydrate metabolism that is caused by a deficiency of the enzyme glucose-6-phosphatase, leading to disturbed glycogenolysis and gluconeogenesis. Patients with GSD Ia are dependent on supplementary exogenous sources of glucose and suffer severe fasting hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia. The primary objective in treatment is to prevent hypoglycemia either by frequent meals, consumption of uncooked cornstarch, continuous gastric drip feeding, or glucose infusion.1Carvalho P.M. Silva N.J. Dias P.G. Porto J.F. Santos L.C. Costa J.M. Glycogen Storage Disease type 1a—a secondary cause for hyperlipidemia: report of five cases.J Diabetes Metab Disord. 2013; 12: 25Crossref PubMed Scopus (16) Google Scholar GSD Ia presenting as neonatal hypoglycemia is uncommon, as most GSD Ia patients are diagnosed at a median age of 3–6 months.2Araoka T. Takeoka H. Abe H. Kishi S. Araki M. Nishioka K. et al.Early diagnosis and treatment may prevent the development of complications in an adult patient with glycogen storage disease type Ia.Intern Med. 2010; 49: 1787-1792Crossref PubMed Scopus (5) Google Scholar Here, we describe a case of neonatal GSD Ia. The diagnosis was confirmed by gene analysis. A 33-year-old woman gave birth vaginally to a male infant at 38 4/7 weeks gestational age, with a birth weight of 3100 g and good Apgar scores. There was no family history of liver or metabolic disease. At age 3 days, the infant was admitted to hospital because of pneumonia. During his hospitalization, he was found to have hypoglycemia and prominent hepatomegaly, liver palpable at 4 cm below the right costal margin, but no splenomegaly. Biochemical tests on Day 7 showed a moderate increase in alanine amino transferase 87 IU/L, aspartate amino transferase 233 IU/L, and fasting hypoglycemia 1.8 mM, (neonatal hypoglycemia defined as glucose <2.6 mM). Biochemical tests on Day 14 showed worsening transaminase levels with alanine amino transferase 216 U/L, and aspartate amino transferase 561 IU/L. On Day 16, he was referred to our hospital for further investigations. On the day of admission, his physical examination showed hepatomegaly with liver palpable at 3.5 cm below the right costal margin and mild wasting of his limbs. His coagulation function was normal. After admission, he had prefeeding glucose levels <2.6 mM on four occasions, which quickly returned to normal after feeding. His fasting blood analyses revealed hypoglycemia, lactic acidosis, and hypertriglyceridemia. On Day 19, before feeding, his glucose level was 1.8 mmol/L, and functional tests showed the absence of a glycemic response and an aggravation of lactic acidosis after injection of glucagon. His thyroid function and insulin/glucose ratio were normal with glucose level at 1.8 mM. On Day 20, his urine was tested for galactosemia. Due to the hypertriglyceridemia, he was fed every 2 hours with a special formula that was galactose-free and contained medium chain triglycerides (MCTs), pending urine results. On Day 20, his blood was sent for genetic testing. His urine test ruled out galactosemia. His fasting blood glucose level was maintained within normal range, lactate and triglycerides levels decreased gradually, and liver function tests also improved substantially by Day 25 (Table 1). Gene analysis revealed a homozygous mutation in exon 1 (c.202 G > A, pG68 R, CM980780, PMID:9700613), which was first reported in 1998.3Sartorato E.L. Reis F.C. Norato D.Y. Hackel C. A novel mutation in a Brazilian patient with glycogen storage disease type 1a.J Inherit Metab Dis. 1998; 21: 447Crossref PubMed Google Scholar His parents refused genetic testing. He was transitioned from MCT formula to regular formula and the parents were taught how to feed him and monitor his glucose before he was discharged home.Table 1Biochemical test results during hospitalization.Blood glucose(3.9–6.1 mM)Alanine amino transferase(0–40 IU/L)Aspartate amino transferase(0–40 IU/L)Triglyceride(0.56–1.7 mM)Lactate(0–4 mM)Day 161.61752592.415.1Day 181.81612743.6810.4Day 214.585863.084.3Day 254.3681111.982.3 Open table in a new tab Hypoglycemia is a life-threatening problem in patients with GSD Ia. More commonly, patients present at around age 3 months with a protruding abdomen due to marked hepatomegaly. Our patient was diagnosed during the neonatal period, and neonatal GSD has only been reported occasionally.4Hufton B.R. Wharton B.A. Glycogen storage disease (type I) presenting in the neonatal period.Arch Dis Child. 1982; 57: 309-311Crossref PubMed Scopus (5) Google Scholar Unlike long chain triglycerides, MCTs are not incorporated into chylomicrons, and the released medium-chain fatty acids enter mitochondria without the carnitine system that is essential for long-chain fatty acids to pass through the mitochondrial membrane. Patients with GSD Ia do not require special formula, although Nagasaka et al5Nagasaka H. Hirano K. Ohtake A. Miida T. Takatani T. Murayama K. et al.Improvements of hypertriglyceridemia and hyperlacticemia in Japanese children with glycogen storage disease type Ia by medium-chain triglyceride milk.Eur J Pediatr. 2007; 166: 1009-1016Crossref PubMed Scopus (19) Google Scholar found that MCT milk helped lower blood triglyceride levels and raise HDL cholesterol levels in GSD Ia patients. Before we ruled out galactosemia in our patient with hypertriglyceridemia, we fed a special galactose-free, MCT formula. After we fed him every 2 hours, his glucose levels were maintained in the normal range, and the hypertriglyceridemia and lactic acidosis gradually improved. The human glucose-6-phosphatase gene was isolated by Lei et al,6Lei K.J. Shelly L.L. Pan C.J. Sidbury J.B. Chou J.Y. Mutations in the glucose-6-phosphatase gene that cause glycogen storage disease type 1a.Science. 1993; 262: 580-583Crossref PubMed Scopus (311) Google Scholar and has been localized to chromosome 17 at 17q21. It includes fives exons and codes for a highly hydrophobic protein of 357 amino acids containing nine transmembrane helices. More than 85 mutations (Human Gene Mutation Database; http://www.hgmd.cf.ac.uk) have been identified.7Zhu J. Xing Y. Xing X. Ren A. Ye S. He G. A novel type heterozygous mutation in the glucose-6-phosphatase gene in a Chinese patient with glycogen storage disease Ia.Gene. 2012; 511: 122-124Crossref PubMed Scopus (4) Google Scholar The diagnosis in our patient was confirmed by gene analysis. Hufton and Wharton4Hufton B.R. Wharton B.A. Glycogen storage disease (type I) presenting in the neonatal period.Arch Dis Child. 1982; 57: 309-311Crossref PubMed Scopus (5) Google Scholar also suggested that in the neonatal period, any unexplained metabolic acidosis, hypoglycemia, hepatomegaly, or hyperlipidemia merits the consideration of GSD in the differential diagnosis. Complete sequencing of the GSD Ia genes allows diagnosis in nearly all patients with evocative clinical and biochemical signs of GSD Ia,8Rake J.P. ten Berge A.M. Visser G. Verlind E. Niezen-Koning K.E. Buys C.H. et al.Glycogen storage disease type Ia: recent experience with mutation analysis, a summary of mutations reported in the literature and a newly developed diagnostic flow chart.Eur J Pediatr. 2000; 159: 322-330Crossref PubMed Scopus (57) Google Scholar thereby eliminating the need for a liver biopsy. The authors have no conflicts of interest to declare, and no organization has provided any financial support to sponsor this research. The authors would like to express their gratitude to Dr Wendy H. Yee, who helped with the revised manuscript.